An Occlusive Hydrocolloid-Based Patch Is Effective, Feasible, and Safe As a Treatment of Irritant Contact Dermatitis Due to Diabetes Devices in Children and Adolescents with Type 1 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Anna Korsgaard Berg
  • Mads Holmegaard Sørensen
  • Henrik Sigaard Knoth
  • Svensson, Jannet

Irritant contact dermatitis (ICD) occurs frequently with the use of diabetes devices, but no guidelines for treatment exist. Since subsequent devices need intact skin for intended use, quick healing is crucial. Normal wound healing is expected to be 7-10 days. This was a single-center cross-over study that investigated the effectiveness of an occlusive hydrocolloid-based patch versus nonocclusive treatment of ICD. Participants were aged 6-20 years with active ICD caused by using diabetes device. First study period was patch treatment for 3 days. A control arm was initiated if a new ICD occurred within 30 days. ICD healed completely in 21% of the patch group but none in the controls. Itching was reported as an adverse event (AE) in both arms, but only one additional AE was noted in the patch arm: an infection at a different site from investigated. The hydrocolloid-based patch showed signs of faster healing of ICD with no additional AEs, but larger studies are needed.

OriginalsprogEngelsk
TidsskriftDiabetes Technology & Therapeutics
Vol/bind25
Udgave nummer10
Sider (fra-til)736-740
Antal sider5
ISSN1520-9156
DOI
StatusUdgivet - 2023

ID: 370473573